Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. [electronic resource]
Producer: 20180126Description: 1440-1448 p. digitalISSN:- 1523-6536
- Adult
- Aged
- Antineoplastic Agents, Immunological -- therapeutic use
- Cyclophosphamide -- administration & dosage
- Graft vs Host Disease -- etiology
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Lymphoma, Follicular -- complications
- Middle Aged
- Myeloablative Agonists -- therapeutic use
- Recurrence
- Remission Induction
- Rituximab -- administration & dosage
- Salvage Therapy -- methods
- Survival Analysis
- Transplantation Conditioning -- adverse effects
- Transplantation, Homologous
- Treatment Outcome
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.